Condition: Psoriasis of Scalp · Sponsor: University of California, San Francisco
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
This description comes directly from the study's public registry record.
Jeffrey Cheng, MD, PhD · 415 575 0524 · rashes@ucsf.edu
Raymond Cho, MD,PhD
Always discuss trial participation with your own doctor first.
| University of California San Francisco | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05858632